Für diesen Artikel ist leider kein Bild verfügbar.

Medullary Thyroid Carcinoma

Biology, management, and treatment of sporadic and hereditary MTC
Buch | Hardcover
VIII, 325 Seiten
2025 | 2. Second Edition 2025
Springer International Publishing (Verlag)
978-3-031-80395-6 (ISBN)
149,79 inkl. MwSt

After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists.

Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective  tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. 

This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.

What is new?.- Thyroid C-Cell Biology and Oncogenic Transformation.- Histopathology of C cells and medullary thyroid carcinoma.- Epidemiology and clinical presentation of Medullary Thyroid Carcinoma.- Medullary thyroid carcinoma: Imaging.- Calcitonin as a Biomarker for Medullary Thyroid Carcinoma.- Hereditary Medullary Thyroid Cancer, Genotype phenotype correlation.- Pheochromocytomas in Multiple Endocrine Neoplasia type 2.- Primary hyperparathyroidism in Multiple Endocrine Neoplasia 2 Syndrome.- Surgical treatment of  medullary thyroid carcinoma.- Long term follow up in medullary thyroid carcinoma.- Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.

Erscheint lt. Verlag 19.4.2025
Reihe/Serie Recent Results in Cancer Research
Zusatzinfo VIII, 325 p. 48 illus., 30 illus. in color.
Verlagsort Cham
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Schlagworte Calcitonin • Multiple Endocrine Neoplasia Type 2 • Pheochromocytoma • Primary Hyperparathyroidism • tyrosinekinase inhibitor
ISBN-10 3-031-80395-7 / 3031803957
ISBN-13 978-3-031-80395-6 / 9783031803956
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00

von Stein Husebø; Gebhard Mathis; Eva Katharina Masel

Buch | Softcover (2023)
Springer (Verlag)
49,99